Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
US Army
Johnson and Johnson
QuintilesIMS
Federal Trade Commission
Cerilliant
McKinsey
Baxter
US Department of Justice
Express Scripts

Generated: August 17, 2017

DrugPatentWatch Database Preview

Pharmacia And Upjohn Company Profile

« Back to Dashboard

What is the competitive landscape for PHARMACIA AND UPJOHN, and what generic alternatives to PHARMACIA AND UPJOHN drugs are available?

PHARMACIA AND UPJOHN has one hundred and thirty-six approved drugs.

There are nine US patents protecting PHARMACIA AND UPJOHN drugs.

There are two hundred and eleven patent family members on PHARMACIA AND UPJOHN drugs in forty-six countries.

Summary for Applicant: Pharmacia And Upjohn

Patents:9
Tradenames:110
Ingredients:85
NDAs:136
Drug Master File Entries: (click here to view)41
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
PENICILLIN G SODIUM
penicillin g sodium
INJECTABLE;INJECTION061046-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CAVERJECT
alprostadil
INJECTABLE;INJECTION020379-004May 19, 1997APRXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
DELTASONE
prednisone
TABLET;ORAL009986-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CYKLOKAPRON
tranexamic acid
INJECTABLE;INJECTION019281-001Dec 30, 1986APRXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
GENOTROPIN
somatropin recombinant
INJECTABLE;INJECTION020280-006Aug 24, 1995BXRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pharmacia And Upjohn

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000► Subscribe► Subscribe
Pharmacia And Upjohn
PROSTIN E2
dinoprostone
SUPPOSITORY;VAGINAL017810-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003► Subscribe► Subscribe
Pharmacia And Upjohn
FLAVORED COLESTID
colestipol hydrochloride
GRANULE;ORAL017563-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Pharmacia And Upjohn
GENOTROPIN PRESERVATIVE FREE
somatropin recombinant
INJECTABLE;INJECTION020280-003Jan 27, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PHARMACIA AND UPJOHN drugs

Drugname Dosage Strength Tradename Submissiondate
linezolid
Injection2 mg/mL, 100 mL bag
ZYVOX
12/29/2009
linezolid
Injection2 mg/mL, 300 mL bag
ZYVOX
9/1/2009
linezolid
Oral Suspension100 mg/5 mL
ZYVOX
8/3/2009
tolterodine tartrate
Extended-release Capsules2 mg and 4 mg
DETROL LA
7/30/2007
linezolid
Tablets600 mg
ZYVOX
12/21/2005
colestipol hydrochloride
Tablets1 g
COLESTID
8/23/2005

Non-Orange Book Patents for Pharmacia And Upjohn

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,821,047 Monovalent phage display► Subscribe
6,444,813 Linezolid-crystal form II► Subscribe
6,428,954 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,040,136 Enrichment method for variant proteins with altered binding properties► Subscribe
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pharmacia And Upjohn Drugs

Country Document Number Estimated Expiration
TaiwanI293028► Subscribe
South Korea20080044358► Subscribe
Yugoslavia69802► Subscribe
Spain2312422► Subscribe
Hungary0302021► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pharmacia And Upjohn Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0022France► SubscribePRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
00492Netherlands► SubscribePRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
C0046Belgium► SubscribePRODUCT NAME: DOXORUBICIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/96/011/001 19960624
C029/2005Ireland► SubscribeSPC029/2005: 20061023, EXPIRES: 20171112
70030Netherlands► SubscribePRODUCT NAME: IBUTILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, IN HET BIJZONDER HET FUMARAAT; NAT. REGISTRATION NO/DATE: RVG 21286 19970612; FIRST REGISTRATION: GB PL 0032/0212 19960930
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Mallinckrodt
Boehringer Ingelheim
Covington
US Department of Justice
AstraZeneca
Daiichi Sankyo
Federal Trade Commission
Moodys
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot